Directory
Portfolio companies.
34,000+ PE-backed.
Active investments and exits across European private equity portfolios.
Filter by sector, geography, status. Find the right deal comp in seconds.
Active deals
12
currently held
Exits tracked
7
hand-checked
Sectors covered
1
across the portfolio
Countries covered
1
from every market
Latest activity
Caledonia InvestmentscapitalCapital Event · capital-cancellation-shares · Capital structure change1 week agoCapital Event · capital-cancellation-shares · Capital structure change
capitalCaledonia InvestmentscapitalCapital Event · capital-cancellation-shares · Capital structure change1 week agoCapital Event · capital-cancellation-shares · Capital structure change
capitalCaledonia InvestmentscapitalCapital Event · capital-cancellation-shares · Capital structure change1 week agoCapital Event · capital-cancellation-shares · Capital structure change
capital
Elaia PartnersadminCEO change · Departure of CEO Gire, Philippe · CEO departure · leadership transition underway2 weeks agoCEO change · Departure of CEO Gire, Philippe · CEO departure · leadership transition underway
adminLauxera Capital PartnersadminBoard change · Management board member change: et Directeur général délégué Fracchia, Edoardo · Change in the management board1 month agoBoard change · Management board member change: et Directeur général délégué Fracchia, Edoardo · Change in the management board
admin18 companies matching
Provell Pharmaceuticals
Flerie Invest
United StatesSector
Pharma
InvestorFlerie
Entry
2013
Hold
12yr
Exit
2025
Acer Therapeutics
TVM Life Science Ventures
United StatesSector
Pharma
InvestorTVM Capital Life Science
Entry
2015
Hold
8yr
Exit
2023
to Zevra Therapeutics
The Ritedose Corporation
Novo Holdings Seed Investments
United StatesSector
Pharma
InvestorNovo Holdings
Entry
2017
Hold
5yr
Owners
2
Xeris Biopharma Holdings, Inc (Strongbridge)
HealthCap VI
United StatesSector
Pharma
InvestorHealthCap
Entry
2014
Hold
7yr
Exit
2021
to Xeris Pharmaceuticals
CoLucid Pharmaceuticals
TVM Life Science Ventures
United StatesSector
Pharma
InvestorTVM Capital Life Science
Entry
2015
Hold
2yr
Exit
2017
to Eli Lilly
Fougera Pharmaceuticals Inc. (formerly Nycomed US Inc.)
Nordic Capital (early funds)
United StatesSector
Pharma
InvestorNordic Capital
Entry
2005
Hold
7yr
Exit
2012
to Sandoz (Novartis)
Pharmion Corp.
HealthCap (early funds)
United StatesSector
Pharma
InvestorHealthCap
Entry
2001
Hold
2yr
Exit
2003
Aliri
MED III
United StatesSector
Pharma
InvestorARCHIMED
Entry
2021
Hold
5yr
Laxxon Medical
Evonik Venture Capital
United StatesSector
Pharma
InvestorEvonik Venture Capital
Entry
2022
Hold
4yr
Royalty Pharma
General Atlantic
United StatesSector
Pharma
InvestorGeneral Atlantic
Entry
–
Start Center For Cancer Research
Warburg Pincus Global Growth 14, L.P.
United StatesSector
Pharma
InvestorWarburg Pincus
Entry
–
Zevra Therapeutics
TVM Life Science Ventures
United StatesSector
Pharma
InvestorTVM Capital Life Science
Entry
2023
Hold
3yr
Catalent
Novo Holdings Principal Investments
United StatesSector
Pharma
InvestorNovo Holdings
Entry
2024
Hold
2yr
KalVista Pharmaceuticals
Novo Holdings Principal Investments
United StatesSector
Pharma
InvestorNovo Holdings
Entry
2025
Hold
1yr
Mirum Pharmaceuticals
Novo Holdings Growth Investments
United StatesSector
Pharma
InvestorNovo Holdings
Entry
2018
Hold
8yr
Presidio Pharmaceuticals
Sobera Capital Fund IV
United StatesSector
Pharma
InvestorSobera Capital
Entry
2018
Hold
8yr
Ritedose
Novo Holdings Principal Investments
United StatesSector
Pharma
InvestorNovo Holdings
Entry
2022
Hold
4yr
Rubicon Research
General Atlantic Partners (Bermuda) IV, L.P.
United StatesSector
Pharma
InvestorGeneral Atlantic
Entry
–